Alkermes (ALKS) Income towards Parent Company (2010 - 2026)
Alkermes (ALKS) posted quarterly Income towards Parent Company of $524000.0 for Q2 2026, up 100.79% quarter-over-quarter from -$66.5 million in Q1 2026.
Alkermes (ALKS) Income towards Parent Company (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Income towards Parent Company for 17 consecutive years, with $524000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Income towards Parent Company changed N/A year-over-year to $524000.0; the TTM figure through Jun 2026 stood at -$16.6 million (down 2699.53% YoY), while the FY2025 annual figure was $241.7 million, up 4273.82% from the prior year.
- Income towards Parent Company climbed to $524000.0 in Q2 2026 per ALKS's latest filing, from -$66.5 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $87.7 million in Q4 2022 and bottomed at -$66.5 million in Q1 2026.
- Historically, Income towards Parent Company has averaged -$15.3 million across 5 years, with a median of -$30.1 million in 2022.
- Annual changes were most pronounced in 2022 — Income towards Parent Company sank 1374.79% — and 2025, when it soared 4309.91%.
- Alkermes' Income towards Parent Company stood at $87.7 million in 2022, then sank by 146.58% to -$40.9 million in 2023, then jumped by 102.74% to $1.1 million in 2024, then jumped by 4309.91% to $49.4 million in 2025, then tumbled by 98.94% to $524000.0 in 2026.
- Business Quant data shows ALKS's Income towards Parent Company at $524000.0 in Q2 2026, -$66.5 million in Q1 2026, and $49.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 524,000.00 |
| Mar 31, 2026 | -66.53 Mn |
| Dec 31, 2025 | 49.39 Mn |
| Dec 31, 2024 | 1.12 Mn |
| Sep 30, 2024 | -481,000.00 |
| Jun 30, 2024 | -3.91 Mn |
| Mar 31, 2024 | -2.52 Mn |
| Dec 31, 2023 | -40.86 Mn |
| Sep 30, 2023 | -45.35 Mn |
| Jun 30, 2023 | -42.08 Mn |
| Mar 31, 2023 | -36.52 Mn |
| Dec 31, 2022 | 87.72 Mn |
| Sep 30, 2022 | -63.97 Mn |
| Jun 30, 2022 | -30.14 Mn |
| Mar 31, 2022 | -35.90 Mn |
| Dec 31, 2021 | 125.44 Mn |
| Sep 30, 2021 | -28.99 Mn |
| Jun 30, 2021 | 2.36 Mn |
| Mar 31, 2021 | -22.42 Mn |
| Dec 31, 2020 | -42.64 Mn |